Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
108.64
-7.52 (-6.47%)
At close: May 15, 2026, 4:00 PM EDT
110.10
+1.46 (1.34%)
After-hours: May 15, 2026, 7:36 PM EDT
Inhibrx Biosciences Employees
As of December 31, 2025, Inhibrx Biosciences had 110 total employees, including 109 full-time and 1 part-time employees. The number of employees decreased by 51 or -31.68% compared to the previous year.
Employees
110
Change (1Y)
-51
Growth (1Y)
-31.68%
Revenue / Employee
$11,818
Profits / Employee
-$1,183,500
Market Cap
1.59B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 110 | -51 | -31.68% | 109 | 1 |
| Dec 31, 2024 | 161 | -11 | -6.40% | 156 | 5 |
| Mar 31, 2024 | 176 | - | - | 170 | 6 |
| Dec 31, 2023 | 172 | - | - | 166 | 6 |
Related Stocks
| Company Name | Employees |
|---|---|
| Agios Pharmaceuticals | 540 |
| Vericel | 398 |
| Nurix Therapeutics | 317 |
| Nuvation Bio | 307 |
| Zymeworks | 264 |
| Capricor Therapeutics | 231 |
| uniQure | 221 |
| Precigen | 160 |
INBX News
- 1 day ago - Inhibrx price target raised to $325 from $300 at Stifel - TheFly
- 2 days ago - Inhibrx Reports First Quarter 2026 Financial Results - PRNewsWire
- 5 days ago - Inhibrx’s INBRX-106 shows potential benefit in HNSCC - TheFly
- 5 days ago - Inhibrx Biosciences Transcript: Study update - Transcripts
- 5 days ago - This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know. - Barrons
- 5 days ago - Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy - PRNewsWire
- 8 days ago - Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC - PRNewsWire
- 22 days ago - Inhibrx initiated with an Outperform at LifeSci Capital - TheFly